SCHEMBL4777338

SCHEMBL4777338

CS(=O)(=O)N(Cc1cccc(Cl)c1Cl)c1ccc(N(C=O)CC2(O)CCCCC2)cc1

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.37
GAA P10253 2/20 0.35
LMNA P02545 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MAPK1 P28482 1/20 0.33
MAPT P10636 1/20 0.33
RECQL P46063 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
NPSR1 Q6W5P4 2/20 0.32
HPGD P15428 1/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
TSHR P16473 1/20 0.32
POLB P06746 2/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4777347 0.79 NR1H4 (0.39) ALDH1A1GAALMNAMAPTRECQL
SCHEMBL4776590 0.79 GAA (0.42) ALDH1A1GAALMNASMN1; SMN2MAPK1
SCHEMBL5571819 0.79 SLC6A4 (0.42) ALDH1A1GAALMNAMAPTRECQL
SCHEMBL4775060 0.78 GAA (0.39) ALDH1A1GAALMNASMN1; SMN2MAPT
SCHEMBL4771365 0.77 GAA (0.37) ALDH1A1GAALMNAMAPK1MAPT
SCHEMBL4776553 0.76 RECQL (0.49) ALDH1A1GAASMN1; SMN2MAPK1MAPT
SCHEMBL4777314 0.75 GAA (0.38) ALDH1A1GAALMNAMAPK1MAPT
SCHEMBL4777342 0.75 ALDH1A1 (0.38) ALDH1A1GAALMNASMN1; SMN2MAPT
SCHEMBL4776710 0.74 GAA (0.43) ALDH1A1GAALMNASMN1; SMN2MAPT
SCHEMBL4768221 0.74 GAA (0.37) ALDH1A1GAALMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 ALDH1A1 2159/4885GAA 466/4885LMNA 1022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.